epitope_domain,residues,mab_example,internalization_rate,t_half_hours,percent_internalized_4h,mechanism,recycling_rate,lysosomal_delivery,adc_suitability_score,notes,references
Domain IV (Trastuzumab epitope),557-603,Trastuzumab,Slow,12.5,25,"Clathrin-mediated endocytosis, partial recycling",High (60-70%),Moderate,7.5,Slow internalization but proven ADC efficacy with T-DM1/T-DXd. High DAR compensates for slower uptake.,Austin CD et al. Mol Biol Cell 2004; Lewis Phillips GD et al. Cancer Res 2008
Domain II (Pertuzumab epitope),266-333,Pertuzumab,Very Slow,24.0,15,"Limited internalization, blocks dimerization",Very High (80%),Low,5.0,Not ideal for ADC due to poor internalization. Better for blocking signaling.,Cort√©s J et al. Lancet Oncol 2012
Domain I (N-terminal),23-165,Experimental,Moderate,8.0,35,Clathrin-mediated endocytosis,Moderate (50%),Moderate,6.5,Less clinically validated but reasonable internalization profile.,Structural predictions
Domain III (L2 domain),355-435,Experimental,Moderate,10.0,30,Clathrin-mediated endocytosis,Moderate (55%),Moderate,6.0,"Limited data, structural accessibility may vary.",Structural predictions
Biparatopic (Domain II + IV),266-333 + 557-603,Zanidatamab,Fast,2.5,70,"Receptor clustering, enhanced clathrin-mediated endocytosis, reduced recycling",Low (20%),High,9.5,Biparatopic binding induces receptor clustering and dramatically enhances internalization. Ideal for ADC.,Oganesyan V et al. MAbs 2018; Weisser NE et al. Nat Commun 2023
Cross-linking (2x Domain IV),557-603 (two sites),MM-302 (anti-HER2 immunoliposome),Fast,3.0,65,"Receptor cross-linking, clustering, lipid raft association",Low (25%),High,9.0,Multivalent binding enhances internalization through receptor clustering.,Reynolds JG et al. Mol Cancer Ther 2012
